Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. - Wikidata - awgldk - TriplyDB

Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection.

Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection.

http://www.wikidata.org/entity/Q33398383

about

Effect of adjuvant interferon therapy on hepatitis B virus-related hepatocellular carcinoma: a systematic review Management before hepatectomy for hepatocellular carcinoma with cirrhosis Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis Effects of antiviral therapy on preventing liver tumorigenesis and hepatocellular carcinoma recurrence.2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma Association of adjuvant antiviral therapy with risk of cancer progression and deaths in patients with hepatitis-B-virus-related hepatocellular carcinoma following curative treatment: a nationwide cohort study Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: A meta-analysis with comparison of different types of hepatitis Role of antiviral therapy in reducing recurrence and improving survival in hepatitis B virus-associated hepatocellular carcinoma following curative resection (Review)Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis.Antiviral therapies for hepatitis B virus-related hepatocellular carcinoma.Immunotherapy for hepatocellular carcinoma: From basic research to clinical use.Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis.A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma.Prognostic nomogram for patients with hepatocellular carcinoma underwent adjuvant transarterial chemoembolization following curative resection.Prevention of recurrence after curative treatment for hepatocellular carcinoma.Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives.Antiviral therapy after curative treatment of hepatitis B/C virus-related hepatocellular carcinoma: A systematic review of randomized trials.A systematic review and meta-analysis of adjuvant interferon therapy after curative treatment for patients with viral hepatitis-related hepatocellular carcinoma.Anti-viral therapy to reduce recurrence and improve survival in hepatitis B virus-related hepatocellular carcinoma.Postoperative therapy options for hepatocellular carcinoma.Antiviral therapy decreases recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection: a meta-analysis.Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review.Adjuvant antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after curative treatment: A systematic review and meta-analysis.Immunological landscape and immunotherapy of hepatocellular carcinoma.Immunotherapy in hepatocellular carcinoma: Primed to make a difference?Evaluating the current surgical strategies for hepatocellular carcinoma.How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma?Metformin confers risk reduction for developing hepatocellular carcinoma recurrence after liver resection.Management of chronic hepatitis B in severe liver disease.Contemporary strategies in the management of hepatocellular carcinoma Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.High levels of hepatitis B surface antigen are associated with poorer survival and early recurrence of hepatocellular carcinoma in patients with low hepatitis B viral loads.Comparison of inflammation-based prognostic scores as predictors of tumor recurrence in patients with hepatocellular carcinoma after curative resection.Adjuvant interferon therapy after surgical treatment for hepatitis B/C virus-related hepatocellular carcinoma: A meta-analysis.Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma.Nucleos(t)ide analogs reduce the risk of hepatitis B-associated hepatocellular carcinoma: A can't miss proposition?Shanghai Score: A Prognostic and Adjuvant Treatment-evaluating System Constructed for Chinese Patients with Hepatocellular Carcinoma after Curative Resection.Surrogate endpoint for overall survival in assessment of adjuvant therapies after curative treatment for hepatocellular carcinoma: a re-analysis of meta-analyses of individual patients' data.

P2860

Q26747293-B3A6F927-91C8-49AB-88A0-A19B824B9F25 Q26783874-78FE36A5-F921-40F2-A64D-06BA67F7D3F0 Q26799056-80A73989-37B9-4544-AA6D-3DA9EEE97EF0 Q26998178-C11D69D3-905A-4983-A364-0E1718A15C74 Q27687423-2C07F967-638A-4D47-93EE-63BD8B506781 Q28392783-747BCDD2-0250-4543-A396-80C61E659E7F Q28394414-82D1C955-7C99-43C8-AF2E-4F148175C085 Q33904007-CA822C74-1605-4C1E-AFBC-B81466761B07 Q34265805-558721DB-697A-44E1-B533-3916C334866F Q34993924-39FFE921-60F6-4F0C-B3C0-574F12EDF97B Q34998414-A4FF84F8-6959-4C6D-A6F6-92F4E72A7655 Q35270193-7DB87933-39A6-460C-8E06-4C02362010A8 Q35567765-AE20F12C-38BD-4F4E-9E5A-99A503E82A4E Q35660038-039BF14A-E2BC-4577-835C-4AB33C00A497 Q36821044-DAD6C537-A029-47B1-BE93-468E76568792 Q37725279-C5B872ED-A4AE-4341-A03D-F9D8A359D54F Q38070128-4F5C69EF-A741-4E91-B6CC-B87F74467E6E Q38099680-40E51C61-0AA3-499E-9EDE-B56402135A04 Q38100807-00400E17-EFCF-4143-8C59-F80AAEE1A5CC Q38134777-48A675EC-D2C7-4576-8DA8-42D7FEE8F1F4 Q38174865-8EACA18B-3BA9-4142-8A89-34BEAD05DE5F Q38203306-5369D60C-7DD7-4094-97DA-66D3030AFF95 Q38208945-2739EDB1-BE8D-4909-B72A-2E8A357AF449 Q38239587-2746B80B-CE18-44D2-8A6F-8BEDD77AF0D9 Q38578909-4FE5D458-92F8-4FA4-9690-65EF217BA186 Q38611895-BF1273F4-7BDE-4D31-8F12-2373F20032A1 Q38625948-46D967A8-148B-4DEB-AA2F-F12BD350DF13 Q38630530-BDB5A643-48D3-45B0-822F-8D4995A4959B Q38718402-FB2E75E4-7C3C-4D56-A0F6-F146BD80A1B7 Q39255557-8DA79BC2-11AF-4194-953E-41FBB72C5ED1 Q41619231-EC923148-221D-4179-B194-282530BA6170 Q41659507-A452F793-48AD-4AF5-8E56-2737A1CE823D Q41962614-A562BE3B-8075-44E8-8D6F-9435D5D4D541 Q42185280-1BB86CB4-513C-413A-9ED1-2257B9ACA41D Q44637461-B5E1CC0D-B348-45DD-A533-937276967F08 Q45351713-CB4CC192-3A53-40A4-A187-DB60C58D86D8 Q45352726-A79798AC-8965-4A06-82CC-4602C65D4003 Q45974690-883E9BAE-7B7A-46FD-94A9-A4E3A4248664 Q47093874-6AF81AAE-C832-4739-839F-5BF62703D79F Q47098597-C5EF5BF5-6A7C-4990-913F-B18FEDF132AF

P2860

Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection.

http://www.wikidata.org/entity/Q33398383

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Long-term results of a randomi ...... noma after curative resection.

@ast

Long-term results of a randomi ...... noma after curative resection.

@en

type

label

Long-term results of a randomi ...... noma after curative resection.

@ast

Long-term results of a randomi ...... noma after curative resection.

@en

prefLabel

Long-term results of a randomi ...... noma after curative resection.

@ast

Long-term results of a randomi ...... noma after curative resection.

@en

P1433

Q33398383-700106EF-FF10-4C09-A0A4-6C967A318E06

P1476

Q33398383-63740064-ABBC-450A-B333-BB0D5D8E423E

P2093

Q33398383-0AA21EC3-5790-457A-94E2-BCA9C41B841B

Q33398383-13EA58A3-E249-44F6-9E54-DEC2EB77F6BD

Q33398383-1601DB75-6160-4780-8683-E362B57BDF3D

Q33398383-23CBDB76-11A9-4F68-9566-EF3E2FE52B1E

Q33398383-2A8C5808-F0DF-471C-9C03-1519BAEE46AC

Q33398383-387480B4-ABD1-4302-B3A7-1C2EF9226A60

Q33398383-3B2D4F5B-8A0D-437E-85E7-C47E06CE76A3

Q33398383-3C2FDA61-94FE-46F0-BB58-5875A1959A2E

Q33398383-81B02634-E615-4A1C-9972-200C062AAADE

Q33398383-87E3BE55-9EA8-4103-A18B-9D1964EDD267

P304

Q33398383-48142C55-B708-45E0-9B83-FCA44DFADC24

P31

Q33398383-F0BEC459-C5C6-4278-9752-B112779EF0DF

P356

Q33398383-5713FBE7-D90E-4DE3-BC84-EE34668DB7AF

P407

Q33398383-17CE8A7F-61BC-4455-A51B-6E5D15C4FC64

P433

Q33398383-CEA371A9-B313-40A2-B6E4-5C364570C120

P478

Q33398383-3157875A-E5A9-461A-B57E-1EA15E415857

P50

Q33398383-39EF5C98-B87F-42B5-A6AF-126A87F1C9C2

Q33398383-93211DCD-5325-4183-A3B5-F9D31DA54F6D

P577

Q33398383-E0D371A4-9D44-4A53-8AEB-D6788A762814

P698

Q33398383-12EC123D-4E60-40C3-966B-C3B1925F9322

P921

Q33398383-8047C726-A6E0-47B1-9114-A92814255B33

P356

SLA.0B013E3182363FF9

P1433

Annals of Surgery

P1476

Long-term results of a randomi ...... noma after curative resection.

@en

P2093

Chao-Long Chen

http://www.w3.org/2001/XMLSchema#string

Cheng-Chung Wu

http://www.w3.org/2001/XMLSchema#string

Deng-Yn Lin

http://www.w3.org/2001/XMLSchema#string

Disease Committee of Adjuvant ...... rch Institutes, Zhunan, Taiwan

http://www.w3.org/2001/XMLSchema#string

Gar-Yang Chau

http://www.w3.org/2001/XMLSchema#string

Jacqueline Whang-Peng

http://www.w3.org/2001/XMLSchema#string

King-Tong Mok

http://www.w3.org/2001/XMLSchema#string

Li-Tzong Chen

http://www.w3.org/2001/XMLSchema#string

Long-Bin Jeng

http://www.w3.org/2001/XMLSchema#string

Lung-An Li

http://www.w3.org/2001/XMLSchema#string

P304

8-17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/SLA.0B013E3182363FF9

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

255

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22104564

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial